tiprankstipranks
Trending News
More News >
AstraZeneca Pharma India Limited (IN:ASTRAZEN)
:ASTRAZEN
India Market
Advertisement

AstraZeneca Pharma India Limited (ASTRAZEN) Price & Analysis

Compare
21 Followers

ASTRAZEN Stock Chart & Stats


ASTRAZEN FAQ

What was AstraZeneca Pharma India Limited’s price range in the past 12 months?
AstraZeneca Pharma India Limited lowest stock price was ₹6222.35 and its highest was ₹10653.05 in the past 12 months.
    What is AstraZeneca Pharma India Limited’s market cap?
    AstraZeneca Pharma India Limited’s market cap is ₹216.47B.
      When is AstraZeneca Pharma India Limited’s upcoming earnings report date?
      AstraZeneca Pharma India Limited’s upcoming earnings report date is Aug 14, 2025 which is today.
        How were AstraZeneca Pharma India Limited’s earnings last quarter?
        Currently, no data Available
        Is AstraZeneca Pharma India Limited overvalued?
        According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does AstraZeneca Pharma India Limited pay dividends?
          AstraZeneca Pharma India Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.38%. See more information on AstraZeneca Pharma India Limited dividends here
            What is AstraZeneca Pharma India Limited’s EPS estimate?
            AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does AstraZeneca Pharma India Limited have?
            AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.
              What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?
              Currently, no hedge funds are holding shares in IN:ASTRAZEN

              Company Description

              AstraZeneca Pharma India Limited

              AstraZeneca Pharma India Limited (ASTRAZEN) is a leading biopharmaceutical company engaged in the development, manufacture, and commercialization of prescription medicines. It operates primarily in the healthcare and pharmaceuticals sector, focusing on key therapeutic areas such as oncology, cardiovascular, renal, and metabolic diseases. The company is a subsidiary of AstraZeneca PLC, a global biopharmaceutical company headquartered in the United Kingdom, and leverages its parent company's research and development capabilities to bring innovative treatments to the Indian market.

              AstraZeneca Pharma India Limited (ASTRAZEN) Earnings & Revenues

              ASTRAZEN Stock 12 Month Forecast

              Average Price Target

              ₹9,605.00
              ▲(14.11% Upside)
              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6665":"₹6,665","9606":"₹9,606","7400.25":"₹7,400.3","8135.5":"₹8,135.5","8870.75":"₹8,870.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6665,7400.25,8135.5,8870.75,9606],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8867.91,8924.60923076923,8981.308461538461,9038.007692307692,9094.706923076923,9151.406153846154,9208.105384615385,9264.804615384615,9321.503846153846,9378.203076923077,9434.902307692308,9491.601538461538,9548.30076923077,{"y":9605,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8867.91,8924.60923076923,8981.308461538461,9038.007692307692,9094.706923076923,9151.406153846154,9208.105384615385,9264.804615384615,9321.503846153846,9378.203076923077,9434.902307692308,9491.601538461538,9548.30076923077,{"y":9605,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8867.91,8924.60923076923,8981.308461538461,9038.007692307692,9094.706923076923,9151.406153846154,9208.105384615385,9264.804615384615,9321.503846153846,9378.203076923077,9434.902307692308,9491.601538461538,9548.30076923077,{"y":9605,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7040.96,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6666.64,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7710.97,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7580.77,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6689.76,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7181.83,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7202.86,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6683.54,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8489.51,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8635.96,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9283.89,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8867.91,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8867.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              Alkem Laboratories Ltd.
              GlaxoSmithKline Pharmaceuticals Limited
              Glenmark Pharmaceuticals Limited
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis